Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kortenberg – page 128

1 955 clinical trials in Kortenberg, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kortenberg at a glance
1 955
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 955 trials in Kortenberg

Open in trial search

Study on Maribavir for Treating Cytomegalovirus in Children and Adolescents Post-Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Maribavir
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Study of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Essa Pharma Inc.

Multiple sclerosis

Not recruiting

Study on the Effects of SAR443820 and Gadobutrol in Patients with Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Gadobutrol
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on AVP-786 for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Neoplasm malignant

Not recruiting

Study of BT5528 alone and with nivolumab in patients with advanced solid tumors that have EphA2 protein expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bicycletx Limited

Study on the Effects of Fidrisertib for Treating Fibrodysplasia Ossificans Progressiva in Children and Adults

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Fidrisertib
  • Sponsor:Clementia Pharmaceuticals Inc. An Ipsen Company

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ataxia telangiectasia

Not recruiting

Study on the Effects of EryDex (Dexamethasone Sodium Phosphate) for Children Aged 6-9 with Ataxia Telangiectasia

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Quince Therapeutics S.p.A.

Breast cancer

Not recruiting

Study on the Safety and Effectiveness of Vepdegestrant and PF-07220060 for Adults with ER+/HER2- Advanced or Metastatic Breast Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vepdegestrant
  • Sponsor:Pfizer Inc.

Study on the Safety and Effects of Tolvaptan for Infants and Young Children with Autosomal Recessive Polycystic Kidney Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tolvaptan
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kortenberg

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. The trials aim to evaluate alternative treatment approaches for managing functional dyspepsia and related conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

The research explores on-demand medication use and alternative therapeutic options using alginate formulations, comparing their effectiveness with traditional tapering methods.

02 Digestive Health Studies

Clinical investigations examining treatment optimization for heartburn and reflux conditions. The research focuses on developing evidence-based approaches to reduce long-term medication dependency.

  • Symptom Management
  • Treatment Optimization
  • Medication Reduction Strategies

These trials aim to establish more effective approaches to managing digestive health while minimizing long-term medication use.

03 Primary Care Innovation

Primary care-focused research evaluating novel approaches to medication management in chronic conditions. The studies emphasize patient-centered strategies for reducing unnecessary long-term medication use.

  • Patient-Centered Care
  • Chronic Medicine Management
  • Evidence-Based Deprescribing

This research aims to transform primary care practices by establishing optimal deprescribing protocols for commonly used medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.